Metraipolis › archive › dc_710072bb966b
Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy — Europe PMC PMID:41210307
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41210307
- DOI
- 10.3389/falgy.2025.1661047
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T02:40:49.557Z
- SHA-256 of the archived text
abd060bc03cb06093f72541187bdb716e7bc9cb21e6d6df2a999df77779e6132- Stable URL of this page
https://metraipolis.com/documento/dc_710072bb966b
How to cite
Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy — Europe PMC PMID:41210307 — Europe PMC (en), https://europepmc.org/article/MED/41210307 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_710072bb966b (Metraipolis archive dc_710072bb966b, sha256 abd060bc03cb06093f72541187bdb716e7bc9cb21e6d6df2a999df77779e6132)
BibTeX
@misc{dc710072bb966b,
title = {Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy — Europe PMC PMID:41210307},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41210307},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_710072bb966b; sha256 abd060bc03cb06093f72541187bdb716e7bc9cb21e6d6df2a999df77779e6132},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41210307. Agents can read the archived copy with the MCP tool read_document.